Keyword: Samsung Biologics


Pharma CEOs Take Action on Climate Change

08.11.2022 -

The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate...


Samsung Biologics in $81 Million Deal with Novartis

13.06.2022 -

In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development...

Markets & Companies

Ramping Up Biomanufacturing Capacity

20.04.2022 -

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...


Samsung Biologics to Take Control of Bioepis JV

04.02.2022 -

Samsung Biologics has agreed to buy out partner Biogen’s share of their Samsung Bioepis joint venture for up to $2.3 billion. The South Korean group said the deal will...


GSK in Manufacturing Pact with Samsung Biologics

25.05.2020 - GlaxoSmithKline has agreed an eight-year, $231 million, pact with South Korean CDMO Samsung Biologics to scale up manufacturing of biologics. The capacity Samsung provides will be...

Strategy & Management

The Need for Innovation in Pharmaceutical Manufacturing

08.04.2019 - The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious...


Digitization’s Impact on the Pharmaceutical Industry

05.06.2018 - The digital developments in the healthcare industry, combined with an aging population and enormous scientific progress, pose new challenges for pharmaceutical companies. On the...